- Home
- DAWN vs ARDX Comparison
DAWN vs ARDX Comparison
Compare DAWN & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- ARDX
- Stock Information
- Founded
- DAWN 2018
- ARDX 2007
- Country
- DAWN United States
- ARDX United States
- Employees
- DAWN N/A
- ARDX N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- ARDX Health Care
- Exchange
- DAWN Nasdaq
- ARDX Nasdaq
- Market Cap
- DAWN 1.4B
- ARDX 1.2B
- IPO Year
- DAWN 2021
- ARDX 2014
- Fundamental
- Price
- DAWN $14.78
- ARDX $6.13
- Analyst Decision
- DAWN Strong Buy
- ARDX Strong Buy
- Analyst Count
- DAWN 8
- ARDX 7
- Target Price
- DAWN $35.86
- ARDX $13.00
- AVG Volume (30 Days)
- DAWN 778.3K
- ARDX 2.4M
- Earning Date
- DAWN 11-04-2024
- ARDX 10-29-2024
- Dividend Yield
- DAWN N/A
- ARDX N/A
- EPS Growth
- DAWN N/A
- ARDX N/A
- EPS
- DAWN N/A
- ARDX N/A
- Revenue
- DAWN $8,192,000.00
- ARDX $209,999,000.00
- Revenue This Year
- DAWN N/A
- ARDX $148.78
- Revenue Next Year
- DAWN $206.28
- ARDX $29.57
- P/E Ratio
- DAWN N/A
- ARDX N/A
- Revenue Growth
- DAWN N/A
- ARDX 153.42
- 52 Week Low
- DAWN $9.67
- ARDX $3.16
- 52 Week High
- DAWN $18.07
- ARDX $10.13
- Technical
- Relative Strength Index (RSI)
- DAWN 58.58
- ARDX 53.62
- Support Level
- DAWN $13.58
- ARDX $5.84
- Resistance Level
- DAWN $14.55
- ARDX $6.43
- Average True Range (ATR)
- DAWN 0.61
- ARDX 0.29
- MACD
- DAWN 0.06
- ARDX 0.01
- Stochastic Oscillator
- DAWN 92.57
- ARDX 68.25
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.